Traws Pharma (TRAW) Other financing activities (2012 - 2025)

Traws Pharma (TRAW) posted quarterly Other financing activities of $10000.0 for Q4 2025, up 400.0% quarter-over-quarter from $2000.0 in Q2 2025.

Traws Pharma (TRAW) Other financing activities (2012 - 2025) Analysis & Trends

Traws Pharma (TRAW) has reported Other financing activities for 8 consecutive years, with $10000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Other financing activities changed N/A year-over-year to $10000.0; the TTM figure through Dec 2025 stood at $26000.0 (changed N/A YoY), while the FY2025 annual figure was $26000.0, changed N/A from the prior year.
Other financing activities climbed to $10000.0 in Q4 2025 per TRAW's latest filing, from $2000.0 in the prior quarter.
Across five years, Other financing activities topped out at $480000.0 in Q1 2021 and bottomed at -$456000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.93 Bn	131.07 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.91 Bn	77.92 Bn	3.93 Bn
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn
4	Moderna	58.86 Bn	53.72 Bn	52.00 Mn
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.54 Bn	28.23 Bn	992.69 Mn
7	BioNTech SE	27.88 Bn	9.49 Bn	668.28 Mn
8	Insmed	27.44 Bn	26.28 Bn	358.27 Mn
9	Royalty Pharma	27.35 Bn	26.51 Bn	-
10	Traws Pharma	5.64 Mn	628,851.51	-

Download Data